Table 3. Clinical trials of epigenetic drugs in bladder cancer.

Drug	Combined Therapy	Enzimatic Class	Approval Stage	Status	Indication	Results	Reference/Clinical trial identification
Belinostat	Carboplatin or paclitaxel	HDAC inhibitor	Phase 1/2	Phase 1 concluded, Phase 2 ongoing	Bladder cancer	Four out of fifteen patients had complete or partial response patients had progressive disease with median time to progression of 136 days	NCT00421889
Vorinostat	-	HDAC inhibitor	Phase 2	Terminated for futility	Locally Recurrent or Metastatic Cancer of the Urothelium	No objective response was observedMedian overall survival: 4,3 monthsMedian progression free survival: 1,1 months	NCT00363883
Mocetinostat	-	HDAC inhibitor	Phase 2	Ongoing	Patients with advanced urothelial Carcinoma and inactivating alterations of acetyltransferase genes	Study completion date: December 2017	NCT02236195
FdCyd	Tetrahydrouridine	DNMT inhibitor	Phase 2	Ongoing	Advanced cancer including bladder Cancer	Study completion date: May 2017	NCT00978250
OGX-427	Docetaxel	Antisense oligonucleotide that targets heat shock protein 27	Phase 2	Ongoing	Advanced urothelial Carcinoma	Study completion date: February 2017	NCT01780545